An open-label pilot trial of minocycline in children as a treatment for Angelman syndrome

BMC Neurology

Volumn 14, Issue 1, 2014, Pages

  Grieco, Joseph C ^a   Ciarlone, Stephanie L ^a   Gieron Korthals, Maria ^a   Schoenberg, Mike R ^a,b   Smith, Amanda G ^b   Philpot, Rex M ^a   Heussler, Helen S ^c   Banko, Jessica L ^b   Weeber, Edwin J ^a,b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

^c UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

Angelman syndrome; Ataxia; Autism; Cognitive impairment; Epilepsy; Seizure

Indexed keywords

MINOCYCLINE; ANTIINFECTIVE AGENT;

ADOLESCENT; ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL GLOBAL IMPRESSION SCALE; COMPREHENSION; DIZZINESS; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HAPPY PUPPET SYNDROME; HUMAN; INFLUENZA A; LANGUAGE ABILITY; LETHARGY; LYME DISEASE; MALE; MOTOR PERFORMANCE; OPEN STUDY; OUTCOME ASSESSMENT; PILOT STUDY; PRESCHOOL CHILD; SCHOOL CHILD; SEIZURE; SOMNOLENCE; TREATMENT DURATION; URINARY TRACT INFECTION; VOMITING; WALKING DIFFICULTY; ANGELMAN SYNDROME; CLINICAL TRIAL; COGNITION DISORDERS; COMPLICATION; TREATMENT OUTCOME;

ANGELMAN SYNDROME; ANTI-BACTERIAL AGENTS; CHILD; CHILD, PRESCHOOL; COGNITION DISORDERS; FEMALE; HUMANS; MALE; MINOCYCLINE; PILOT PROJECTS; TREATMENT OUTCOME;

EID: 84923853737     PISSN: None     EISSN: 14712377     Source Type: Journal    
DOI: 10.1186/s12883-014-0232-x     Document Type: Article

References (53)

1. Angelman H: 'Puppet' children a report on three cases. Dev Med Child Neurol 1965, 7(6):681-688.
2. Barry RJ, Leitner RP, Clarke AR, Einfeld SL: Behavioral aspects of Angelman syndrome: a case control study. Am J Med Genet A 2005, 132A(1):8-12.
3. Williams CA: Neurological aspects of the Angelman syndrome. Brain Dev 2005, 27(2):88-94.
4. Horsler K, Oliver C: The behavioural phenotype of Angelman syndrome. J Intellect Disabil Res 2006, 50(Pt 1):33-53.
5. Williams CA: The behavioral phenotype of the Angelman syndrome. Am J Med Genet C: Semin Med Genet 2010, 154C(4):432-437.
6. Pelc K, Cheron G, Dan B: Behavior and neuropsychiatric manifestations in Angelman syndrome. Neuropsychiatr Dis Treat 2008, 4(3):577.
7. Clayton-Smith J, Laan L: Angelman syndrome: a review of the clinical and genetic aspects. J Med Genet 2003, 40(2):87-95.
8. Boyd SG, Harden A, Patton MA: The EEG in early diagnosis of the Angelman (happy puppet) syndrome. Eur J Pediatr 1988, 147(5):508-513.
9. Laan LA, Renier WO, Arts WF, Buntinx IM, Vd Burgt IJ, Stroink H, Beuten J, Zwinderman KH, van Dijk JG, Brouwer OF: Evolution of epilepsy and EEG findings in Angelman syndrome. Epilepsia 1997, 38(2):195-199.
10. Laan LA, Vein AA: Angelman syndrome: is there a characteristic EEG? Brain Dev 2005, 27(2):80-87.
11. Vendrame M, Loddenkemper T, Zarowski M, Gregas M, Shuhaiber H, Sarco DP, Morales A, Nespeca M, Sharpe C, Haas K, Barnes G, Glaze D, Kothare SV: Analysis of EEG patterns and genotypes in patients with Angelman syndrome. Epilepsy Behav 2012, 23(3):261-265.
12. Pelc K, Boyd SG, Cheron G, Dan B: Epilepsy in Angelman syndrome. Seizure 2008, 17(3):211-217.
13. Williams C: Angelman syndrome scientific symposium on the structure and function of UBE3A/E6AP. J Child Neurol 2009, 24(7):904-908.
14. Kishino T, Lalande M, Wagstaff J: UBE3A/E6-AP mutations cause Angelman syndrome. Nat Genet 1997, 15(1):70-73.
15. Margolis SS, Salogiannis J, Lipton DM, Mandel-Brehm C, Wills ZP, Mardinly AR, Hu L, Greer PL, Bikoff JB, Ho HY, Soskis MJ, Sahin M, Greenberg ME: EphB-mediated degradation of the RhoA GEF Ephexin5 relieves a developmental brake on excitatory synapse formation. Cell 2010, 143(3):442-455.
16. Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL: The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. Hum Mol Genet 2008, 17(1):111-118.
17. Rogers JT, Rusiana I, Trotter J, Zhao L, Donaldson E, Pak DT, Babus LW, Peters M, Banko JL, Chavis P: Reelin supplementation enhances cognitive ability, synaptic plasticity, and dendritic spine density. Learn Mem 2011, 18(9):558-564.
18. Daily JL, Nash K, Jinwal U, Golde T, Rogers J, Peters MM, Burdine RD, Dickey C, Banko JL, Weeber EJ: Adeno-associated virus-mediated rescue of the cognitive defects in a mouse model for Angelman syndrome. PLoS One 2011, 6(12):e27221.
19. Huang H-S, Allen JA, Mabb AM, King IF, Miriyala J, Taylor-Blake B, Sciaky N, Dutton JW, Lee H-M, Chen X: Topoisomerase inhibitors unsilence the dormant allele of Ube3a in neurons. Nature 2012, 481(7380):185-189.
20. Van Woerden GM, Harris KD, Hojjati MR, Gustin RM, Qiu S, de Avila FR, Jiang Y-h, Elgersma Y, Weeber EJ: Rescue of neurological deficits in a mouse model for Angelman syndrome by reduction of αCaMKII inhibitory phosphorylation. Nat Neurosci 2007, 10(3):280-282.
21. Ulgen BO, Field MG, Qureshi W, Knight RA, Stephanou A, Latchman DS, Vasquez D, Barry SP, Saravolatz L 2nd, Scarabelli GM, Faggian G, Mazzucco A, Saravolatz L, Chen-Scarabelli C, Scarabelli TM: The role of minocycline in ischemia-reperfusion injury: a comprehensive review of an old drug with new implications. Recent Pat Cardiovasc Drug Discov 2011, 6(2):123-132.
22. Macdonald H, Kelly RG, Allen ES, Noble JF, Kanegis LA: Pharmacokinetic studies on minocycline in man. Clin Pharmacol Ther 1973, 14(5):852-861.
23. Bilousova TV, Dansie L, Ngo M, Aye J, Charles JR, Ethell DW, Ethell IM: Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009, 46(2):94-102.
24. Kernt M, Neubauer AS, Eibl KH, Wolf A, Ulbig MW, Kampik A, Hirneiss C: Minocycline is cytoprotective in human trabecular meshwork cells and optic nerve head astrocytes by increasing expression of XIAP, survivin, and Bcl-2. Clin Ophthalmol (Auckland, NZ) 2010, 4:591.
25. Mehrotra S, Pecaut MJ, Gridley DS: Minocycline modulates cytokine and gene expression profiles in the brain after whole-body exposure to radiation. In vivo 2014, 28(1):21-32.
26. Thomas GM, Huganir RL: MAPK cascade signalling and synaptic plasticity. Nat Rev Neurosci 2004, 5(3):173-183.
27. Jin LJ, Schlesinger F, Guan Q, Song YP, Nie ZY: The two different effects of the potential neuroprotective compound minocycline on AMPA-type glutamate receptors. Pharmacology 2012, 89(3-4):156-162.
28. Chen H, Manev H: Effects of minocycline on cocaine sensitization and phosphorylation of GluR1 receptors in 5-lipoxygenase deficient mice. Neuropharmacology 2011, 60(7-8):1058-1063.
29. Manev H, Manev R: Interactions with GluR1 AMPA receptors could influence the therapeutic usefulness of minocycline in ALS. Amyotroph Lateral Scler 2009, 10(5-6):416-417.
30. Goni-Allo B, Ramos M, Jordán J, Aguirre N: In vivo studies on the protective role of minocycline against excitotoxicity caused by malonate or N-methyl-D-aspartate. Exp Neurol 2005, 191(2):326-330.
31. Greer PL, Hanayama R, Bloodgood BL, Mardinly AR, Lipton DM, Flavell SW, Kim T-K, Griffith EC, Waldon Z, Maehr R: The Angelman Syndrome protein Ube3A regulates synapse development by ubiquitinating arc. Cell 2010, 140(5):704-716.
32. Fujita Y, Ishima T, Kunitachi S, Hagiwara H, Zhang L, Iyo M, Hashimoto K: Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline. Prog Neuro-Psychopharmacol Biol Psychiatry 2008, 32(2):336-339.
33. Pignatelli M, Piccinin S, Molinaro G, Di Menna L, Riozzi B, Cannella M, Motolese M, Vetere G, Catania MV, Battaglia G: Changes in mGlu5 receptor-dependent synaptic plasticity and coupling to homer proteins in the hippocampus of Ube3A hemizygous mice modeling angelman syndrome. The Journal of neuroscience 2014, 34(13):4558-4566.
34. Weeber EJ, Jiang Y-H, Elgersma Y, Varga AW, Carrasquillo Y, Brown SE, Christian JM, Mirnikjoo B, Silva A, Beaudet AL: Derangements of hippocampal calcium/calmodulin-dependent protein kinase II in a mouse model for Angelman mental retardation syndrome. The Journal of neuroscience 2003, 23(7):2634-2644.
35. Quinlan EM, Philpot BD, Huganir RL, Bear MF: Rapid, experience-dependent expression of synaptic NMDA receptors in visual cortex in vivo. Nat Neurosci 1999, 2(4):352-357.
36. Paribello C, Tao L, Folino A, Berry-Kravis E, Tranfaglia M, Ethell IM, Ethell DW: Open-label add-on treatment trial of minocycline in fragile X syndrome. BMC Neurol 2010, 10:91.
37. Yong VW, Wells J, Giuliani F, Casha S, Power C, Metz LM: The promise of minocycline in neurology. Lancet Neurol 2004, 3(12):744-751.
38. Garrido-Mesa N, Zarzuelo A, Galvez J: Minocycline: far beyond an antibiotic. Br J Pharmacol 2013, 169(2):337-352.
39. Egawa K, Kitagawa K, Inoue K, Takayama M, Takayama C, Saitoh S, Kishino T, Kitagawa M, Fukuda A: Decreased tonic inhibition in cerebellar granule cells causes motor dysfunction in a mouse model of Angelman syndrome. Sci Transl Med 2012, 4(163):163ra157-163ra157.
40. Goulden V, Glass D, Cunliffe WJ: Safety of long-term high-dose minocycline in the treatment of acne. Br J Dermatol 1996, 134(4):693-695.
41. Fanning WL, Gump DW, Sofferman RA: Side effects of minocycline: a double-blind study. Antimicrob Agents Chemother 1977, 11(4):712-717.
42. Cohen J: Statistical Power Analysis for the Behavioral Sciences. Routledge; 2013.
43. Black MM, Matula K: Essentials of Bayley Scales of Infant Development II Assessment. New York: John Wiley & Sons, Inc; 2000.
44. NINDS Common Data Elements. National Institutes of Health 2014, [ http://www.commondataelements.ninds.nih.gov/epilepsy.aspx#tab=Data_Standards ]. Web.
45. Peters SU, Goddard-Finegold J, Beaudet AL, Madduri N, Turcich M, Bacino CA: Cognitive and adaptive behavior profiles of children with Angelman syndrome. Am J Med Genet A 2004, 128(2):110-113.
46. DeWitt M, Schreck K, Mulick J: Use of bayley scales in individuals with profound mental retardation: comparison of the first and second editions. J Dev Phys Disabil 1998, 10(3):307-313.
47. Peters SU, Bird LM, Kimonis V, Glaze DG, Shinawi LM, Bichell TJ, Barbieri-Welge R, Nespeca M, Anselm I, Waisbren S: Double-blind therapeutic trial in Angelman syndrome using betaine and folic acid. Am J Med Genet A 2010, 152(8):1994-2001.
48. Loring DW, Bowden SC: The STROBE statement and neuropsychology: lighting the way toward evidence-based practice. Clin Neuropsychol 2013, 1-19. ahead-of-print.
49. Pearson Education: Using the Bayley Scales of Infant and Toddler Development, 3rd Edition, to Assess Individuals with Severe Delays, 2008. [ http://images.pearsonassessments.com/images/tmrs/tmrs_rg/TechReport1.pdf?WT.mc_id=TMRS_Bayley_III_Technical_Report_1 ]. Web.
50. Loring DW, Lowenstein DH, Barbaro NM, Fureman BE, Odenkirchen J, Jacobs MP, Austin JK, Dlugos DJ, French JA, Gaillard WD: Common data elements in epilepsy research: development and implementation of the NINDS epilepsy CDE project. Epilepsia 2011, 52(6):1186-1191.
51. Thibert RL, Pfeifer HH, Larson AM, Raby AR, Reynolds AA, Morgan AK, Thiele EA: Low glycemic index treatment for seizures in Angelman syndrome. Epilepsia 2012, 53(9):1498-1502.
52. Bird LM, Tan WH, Bacino CA, Peters SU, Skinner SA, Anselm I, Barbieri-Welge R, Bauer-Carlin A, Gentile JK, Glaze DG, Horowitz LT, Mohan KN, Nespeca MP, Sahoo T, Sarco D, Waisbren SE, Beaudet AL: A therapeutic trial of pro-methylation dietary supplements in Angelman syndrome. Am J Med Genet A 2011, 155A(12):2956-2963.
53. Busner J, Targum SD: The clinical global impressions scale: applying a research tool in clinical practice. Psychiatry 2007, 4(7):28-37.